Neogen Chemicals Ltd (BOM:542665) (Q2 2027) Earnings Call Highlights: 42% Revenue

NEOGEN CORP (NEOG) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On March 2, 2026, Neogen Corporation (“ Neogen ”) announced that it had entered into a definitive agreement to sell its global Genomics business to Zoetis Inc. (“ Zoetis ”). This transaction is subject to customary closing conditions and regulatory approva

Neogen Chemicals (NSE: NEOGEN) reported Q2 FY27 earnings with a 144% YoY profit increase to INR 8 crore, beating EPS estimates but missing revenue forecasts. Revenue grew 42% to INR 296 crore, driven by a 585% surge in battery chemicals. The stock fell 3.5% post-results.

NEOG reported Q3 revenue of $222.8M, beating estimates by 7%, and adjusted EPS of $0.08, beating by 50%. Adjusted EBITDA was $41.6M, an 18.7% margin. The company raised FY revenue guidance to $887.5M and EBITDA to $182M. Management highlighted commercial execution gains, innovation investments, and operational efficiency improvements.

Neogen reported Q1 fiscal 2027 revenue of $222.8M, up 6.5%, with Food Safety and Animal Safety segments growing 7.4% and 4.2%, respectively. Gross margin improved to 47.4%. Adjusted net income rose to $17.5M. The company raised its fiscal 2027 revenue guidance to $885M-$890M and adjusted EBITDA guidance to $181M-$183M.

Neogen (NEOG) received an FDA warning over a contaminated veterinary product. The company's response and any follow-up actions will be key for investors to monitor. Additionally, investors should review the company's management structure and compensation packages.

Neogen Corporation reported Q1 FY2027 revenue of $222.8 million, up 6.5%, and adjusted EPS of $0.08, exceeding estimates. GAAP EPS was negative at $0.05. Shares initially rose 8% after hours. The company raised annual guidance, citing higher margins and positive free cash flow.